AUCTORES
Globalize your Research
Research Article
*Corresponding Author: Mohamed Zaeim Hafez Ahmed, Physiology department, Faculty of medicine, Al Azhar University, Egypt.
Citation: Ahmedel-Sayed Nour El-Deen, Ahmad Gadalla, Hafez Ahmed MZ, Elsayed Mohamed EE, Ibrahim Thabet RH, et all., (2023), Protective effect of vitamin D and Doxorubicin on Induced Cardiotoxicity in Male Albino Rats, J. Pharmaceutics and Pharmacology Research, 6(4); DOI: 10.31579/2693-7247/132
Copyright: © 2023, Mohamed Zaeim Hafez Ahmed. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: 24 April 2023 | Accepted: 05 May 2023 | Published: 15 May 2023
Keywords: cardiotoxicity; doxorubicin; male albino rates, Vitamin D supplementation
Background & Objectives: Cardiotoxicity can manifest as abnormalities in the electrical representations of heart beats as seen by an electrocardiogram, such as a prolongation in the interval between the Q wave and T wave (QT interval), decreased amplitude of QRS complexes, a decrease in left ventricular ejection fraction, and cardiomyopathy. In order to assess the potential protective impact of vitamin D (Vit D) against the cardiotoxicity caused by doxorubicin (Dox).
Materials and Methods: The animal house of Al Azhar University sold 28 adult males Wistar albino rats of the local strain, weighing (850±150 g). Seven of them were housed in cages and given free access to food, water and kept in standardized settings with 12-hour light/dark cycles and 24-degree temperatures. Prior to the trial, they were held for two weeks to acclimatize to the new surroundings. The animals randomly divided into four groups of 7 rats in each, group 1(control group), group 2 (doxorubicin treated group), group 3 (Vit D pre-treated group), group 4 (Vit D and doxorubicin co-treated group).
Results: Serum calcium, creatine kinase, cardiac troponin concentration, and malondialdehyde levels in cardiac tissue significantly increased among group 2 (92.76±3.60, 95.51±5.13, 1.05±0.15, 9.70±0.82) than controls (14.07±0.84,15.44±0.65, 0.02±0.01, 6.09±0.27), group 3 (42.91±7.66, 38.60±2.47, 0.23±0.10, 7.93±0.33) and group 4 (30.29±2.06, 32.01±2.39, 0.37±0.09, 7.27±0.43), respectively (P<0.001).
Conclusion: The current results demonstrate that vitamin D supplementation in the diet, whether mild or moderate, was cardioprotective and didn’t interfere with Dox ability to treat cancer in rats. It is reasonable to conduct more research to determine the ideal vitamin D dosages required to enhance heart functions without reducing Dox effectiveness.
Cardiotoxicity may manifest as irregularities in the electrical representations of heartbeats on an echocardiography (ECG), such as increase in the QT interval, a decrease in the amplitude of QRS complexes, and decrease in left ventricular ejection fraction, as well as cardiomyopathy [1].
The anti-cancer drug doxorubicin (Dox) is extensively used in chemotherapy; however, the main side effects prevent it from being utilized in clinical settings is cardiotoxicity [2].
The pathogenesis of Dox-induced cardiotoxicity involves the same to involve number of mechanisms, as oxidative stress-induced cell damage, lipid peroxidation, mitochondrial damage, inflammation, and apoptosis. The elevation free radical production and oxidative stress are the main contributors to Dox-induced cardiotoxicity [2].
The following methods are regarded to be the main ways that Dox, they are easily absorbed by cells and concentrate. Deoxyribonucleic acid (DNA) biosynthesis can be stopped by Dox ability to block DNA intercalation. This drug makes hydrogen bonds with guanine to create ternary Dox-DNA-topoisomerase II complexes, which activate DNA damage responses and ultimately cause cell death. This drug has a great affinity for ECG base pair sites [3].
Vitamin D receptors are present in several tissues, including endothelial cells, vascular smooth muscle cells, and cardiomyocytes. Additionally, it has been shown to have an impact on inflammation, cell differentiation, and proliferation [4].
Several human observational studies supported these experimental results raise the possibility that vitamin D or its equivalents may prove therapeutically advantageous in the prevention or treatment of cardiovascular disease [5].
Furthermore, interleukin and C-reactive protein levels as well as congestive heart failure and low vitamin D levels all of them have been associated. Due to that vitamin D acts as a natural vascular defender factor. In fact, both hypertension, cardiac hypertrophy, enhanced renin
expression, and higher angiotensin II concentration are all signs of experimental vitamin D deficiency [6].
Therefore, the aim of this study was to investigate whether vitamin D could provide cardiotoxicity protection against doxorubicin.
Animal Selection
A total of 28 mature male albino rats of the local strain (To avoid effect of feminine hormonal changes on the heart) from the Al Azhar University's animal house for 850±150 g. Seven of them were housed in a cage, and they given free access to food, water, and kept in standardised circumstances with 12-hour light/dark cycles and 24-degree temperatures. The university's animal ethics committee gave its approval to experimental methods (aproval ID, AZHPHY2021). Prior to the trial, they were held for two weeks to acclimate to the new surroundings.
Chemicals
Vitamin D (cholecalciferol) was administered in drops with a concentration of 2800 IU/ml, each containing 100 IU of Vitamin D, in DOX 50mg vials containing 25 ml of red solution, which were purchased from Pfizer Egypt Pharmaceutical Company (Vidrop, Medical Union Pharmaceuticals, Abu-Sultan, Ismailia, Egypt).
Experimental Procedures: All procedures were conducted at Al-Azhar University Assuit, Egypt.
Induction of cardiotoxicity: Doxorubicin, at a dose of 8.0 mg/kg, was administered once intraperitoneally after an adjustment time to cause cardiomyopathy. [7]
The animals were randomly divided into 4 groups of 7 rats in each:
Group 1(control group): standard control received intraperitoneal (i.p.) normal saline 5 ml/kg body weight for 4 weeks,
Group 2 (Doxorubicin treated group): the doxorubicin (DOX) group got a single intravenous dosage of DOX (25 mg/kg). [8]
Group 3 (Vit D Pre-treated group): Rats used as the pretreatment Vit D group received daily vitamin D supplements of 10,000 IU per 100 g of body weight for 4 weeks, followed by an intravenous injection of DOX (25 mg/kg).
Group 4 (Vit D and doxorubicin Co-treated group): Rats used in the doxorubicin plus vitamin D (DOX+Vit D) group received a single intravenous dose of DOX (25 mg/kg) and 10000 IU of vitamin D per 100 g of body weight each day for 4 weeks on the first day of the experiment.
Collection of blood samples: Each rat had a tail vein removed, and fresh blood was drawn into tubes containing potassium oxalate and sodium fluoride. Measurements of cardiac troponin I, creatine kinase isoenzyme-MB (CK-MB) activity, and serum calcium were made using blood samples.
Biochemical parameters
Serum calcium: A Hitachi (model Z-5700) atomic absorption spectrophotometer graphite-furnace atomizer with modifications was used to measure the serum calcium level [9].
Serum creatine kinase: The serum CK-MB activity was determined spectrophotometrically in line with the suggested procedures using commercial kits obtained from spectrum diagnostics, Cairo, Egypt [10].
Serum level of cardiac troponin I: The serum level of cardiac troponin I (c-TnI) was measured using an enzyme linked immunosorbent assay (ELISA) kit produced by life diagnostics Inc. in accordance with the manufacturer's instructions [10].
Assessment of systolic blood pressure (SBP): measured in conscious rats using a non-invasive blood pressure monitor (tail-cuff plethysmograph) from (Ugo in Basile, Italy), in accordance with the standards specified by Irvine et al., [11]. On days 1 and 30, SBP measured one hour after the administration of drug. Back-to-back measurements of five were done. To calculate the value, the lowest three systolic blood pressure values were averaged.[12]
Electrocardiogram (ECG): Rats got 50 mg/kg sodium pentobarbital ip injection at the conclusion of the experiment [13]. Rats given general anaesthesia before being placed supine on a board, where the ECG continuously recorded using industry-standard lead II (right forelimb to left hind limb), which is artifact-free. Needles electrodes inserted into the pads of each rat's paws and connected to a Biocare ECG 101 (Shenzhen Biocare Electronics Co., Ltd., China). The ECG used to determine the length and amplitude of the Pwave, QRS complex, and ST segment alterations [14]
Measurement of MDA, SOD and GSH in cardiac tissue
The cardiac tissues were subsequently immersed in cold saline (1:10 w/v), then homogenised using a machine. The levels of superoxide dismutase (SOD), malondialdehyde (MDA), and glutathione (GSH) in cardiac tissues then determined by centrifuging the supernatant at 3000 rpm [15].
Statistical analysis
Following the analysis of variance (ANOVA) test, the data were examined using the least significant difference (LSD) post hoc test in Statistical Package for the Social Sciences (SPSS) 23. The information was converted to mean standard deviation (SD). A value is considered significant level when P≤0.05.
A total of 28 male albino rats included in our study, it was discovered that the serum calcium levels of group 2 significantly higher (92.76±3.60) than control group (14.07±0.84), group 3 (42.91±7.66), and group 4 (30.29±2.06) (P 0.001) (Table 1).
| Serum calcium | Mean ±SD | Range | F | P value | 95% CI | |
| Lower | Upper | |||||
| Normal control group (N=7) | 14.07±0.84 | 12.90-15.20 | 421.245 | <0> | 13.29 | 14.85 |
| Doxorubicin treated group (N=7) | 92.76±3.60 | 97.80-87.90 | 89.43 | 96.08 | ||
| Vit D Pre-treated group (N=7) | 42.91±7.66 | 33.70-52.40 | 35.83 | 50.00 | ||
| Vit D and doxorubicin Co-treated group (N=7) | 30.29±2.06 | 27.20-33.10 | 28.38 | 32.19 | ||
Post Hoc P (Mean Difference) | P1<0> | |||||
Table 1: Serum calcium among the studied groups of rats
F: One way ANOVA test. *Significant. CI: Confidence interval for Mean.
P1: normal control group compared doxorubicin treated group.
P2: normal control group compared vit D Pre-treated group.
P3: normal control group compared vit D and doxorubicin Co-treated group.
P4: doxorubicin treated group compared vit D Pre-treated group.
P5: doxorubicin treated group compared vit D and doxorubicin Co-treated group.
P6: vit D Pre-treated group compared vit D and doxorubicin Co-treated group.
Additionally, serum creatine kinase levels substantially higher in group 2 (95.51±5.13) than in the control group (15.44±0.65), group 3 (38.60±2.47), and group 4 (32.01±2.39) groups (P<0>Table2).
| Serum creatine kinase (CK-MB) (IU/L) | Mean ±SD | Range | F | P value | 95% CI | ||
| Lower | Upper | ||||||
| Normal control group (N=7) | 15.44±0.65 | 14.66-16.40 | 880.608 | <0> | 14.84 | 16.04 | |
| Doxorubicin treated group (N=7) | 95.51±5.13 | 89.30-102.70 | 90.77 | 100.26 | |||
| Vit D Pre-treated group (N=7) | 38.60±2.47 | 35.60-42.60 | 36.31 | 40.89 | |||
| Vit D and doxorubicin Co-treated group (N=7) | 32.01±2.39 | 29.60-35.70 | 29.81 | 34.22 | |||
Post Hoc P (Mean Difference) | P1<0 P6=0.001(6.59)> | ||||||
Table 2: Serum creatine kinase among the studied groups of rats
F: One way ANOVA test. *Significant. CI: Confidence interval for Mean.
P1: normal control group compared doxorubicin treated group.
P2: normal control group compared vit D Pre-treated group.
P3: normal control group compared vit D and doxorubicin Co-treated group.
P4: doxorubicin treated group compared vit D Pre-treated group.
P5: doxorubicin treated group compared vit D and doxorubicin Co-treated group.
P6: vit D Pre-treated group compared vit D and doxorubicin Co-treated group.
Moreover, serum cardiac troponin concentration substantially higher in group 2 (1.05±0.15) compared to control group (0.02±0.01), group 3 (0.23±0.10), and group 4 (0.37±0.09), (P<0> (Table 3) and (Figure 1).
| Serum level of cardiac troponin I (ng/ml) | Mean ±SD | Range | F | P value | 95% CI | ||
| Lower | Upper | ||||||
| Normal control group (N=7) | 0.02±0.01 | 0.01-0.03 | 138.035 | <0> | 0.01 | 0.02 | |
| Doxorubicin treated group (N=7) | 1.05±0.15 | 0.88-1.24 | 0.92 | 1.18 | |||
| Vit D Pre-treated group (N=7) | 0.23±0.10 | 0.10-0.38 | 0.13 | 0.32 | |||
| Vit D and doxorubicin Co-treated group (N=7) | 0.37±0.09 | 0.25-0.52 | 0.29 | 0.46 | |||
Post Hoc P (Mean Difference) | P1<0 P2=0.001(0.21), P6=0.012(0.15)> | ||||||
Table 3: Serum level of cardiac troponin I among the studied groups of rats
F: One way ANOVA test. *Significant. CI: Confidence interval for Mean.
P1: normal control group compared doxorubicin treated group.
P2: normal control group compared vit D Pre-treated group.
P3: normal control group compared vit D and doxorubicin Co-treated group.
P4: doxorubicin treated group compared vit D Pre-treated group.
P5: doxorubicin treated group compared vit D and doxorubicin Co-treated group.
P6: vit D Pre-treated group compared vit D and doxorubicin Co-treated group.
Figure 1. Distribution of Serum level of cardiac troponin I among the studied groups of rats.
While, malondialdehyde levels in cardiac tissue considerably higher in group 2 (9.70±0.82) compared to control group (6.09±0.27), group 3 (7.93±0.33) and group 4 (7.27±0.43), (P<0>(Table 4).
| Variable | Mean ±SD | Range | F | P value | 95% CI | ||
| Lower | Upper | ||||||
| MDA in cardiac tissue (nmol/gprotein) | |||||||
| Normal control group (N=7) | 6.09±0.27 | 5.70-6.50 | 61.549 | <0> | 5.83 | 6.34 | |
| Doxorubicin treated group (N=7) | 9.70±0.82 | 8.70-11.10 | 8.94 | 10.46 | |||
| Vit D Pre-treated group (N=7) | 7.93±0.33 | 7.50-8.40 | 8.23 | 7.50 | |||
| Vit D and doxorubicin Co-treated group (N=7) | 7.27±0.43 | 6.80-8.10 | 6.80 | 8.10 | |||
Post Hoc P (Mean Difference) | P1<0 P6=0.024(0.66)> | ||||||
| SOD in cardiac tissue (IU/mg protein) | |||||||
| Normal control group (N=7) | 106.14±6.44 | 98.00-115.00 | 84.575 | <0> | 100.19 | 112.10 | |
| Doxorubicin treated group (N=7) | 50.86±6.52 | 42.00-61.00 | 44.83 | 56.88 | |||
| Vit D Pre-treated group (N=7) | 77.14±7.73 | 66.00-89.00 | 69.99 | 84.30 | |||
| Vit D and doxorubicin Co-treated group (N=7) | 65.14±6.23 | 58.00-78.00 | 59.38 | 70.90 | |||
Post Hoc P (Mean Difference) | P1<0 P5=0.001(14.29), P6=0.003(12.00)> | ||||||
| GSH in cardiac tissue (µg/g wet wt) | |||||||
| Normal control group (N=7) | 219.57±10.91 | 207.00-234.00 | 88.015 | <0> | 209.48 | 229.66 | |
| Doxorubicin treated group (N=7) | 145.00±7.59 | 137.00-157.00 | 137.98 | 152.02 | |||
| Vit D Pre-treated group (N=7) | 175.71±8.52 | 164.00-188.00 | 167.84 | 183.59 | |||
| Vit D and doxorubicin Co-treated group (N=7) | 160.86±8.84 | 152.00-178.00 | 152.68 | 169.03 | |||
Post Hoc P (Mean Difference) | P1<0 P5=0.003(15.86), P6=0.005> | ||||||
Table 4: Oxidative stress indicators in cardiac tissue among the studied groups of rats.
MDA: Malondialdehyde. SOD: Superoxide dismutase. GSH: Glutathione.
F: One way ANOVA test. *Significant. CI: Confidence interval for Mean.
P1: normal control group compared doxorubicin treated group.
P2: normal control group compared vit D Pre-treated group.
P3: normal control group compared vit D and doxorubicin Co-treated group.
P4: doxorubicin treated group compared vit D Pre-treated group.
P5: doxorubicin treated group compared vit D and doxorubicin Co-treated group.
P6: vit D Pre-treated group compared vit D and doxorubicin Co-treated group.
Multiple cancer types can be successfully treated with doxorubicin (Dox), including triple negative breast cancer (TNBC). However, the use of Dox is constrained because of its cardiotoxic adverse effects, which are caused by increase of oxidative stress [16]. Cardiomyopathy, a prolonged QT interval, a smaller QRS complex, a decrease left ventricular ejection fraction, and long delayed between Q and T waves are a few examples of abnormalities in the electrical representations of heartbeats on ECG that indicator of cardiotoxicity presence [17].
Dox is converted into a reactive metabolite by the enzymes as NADPH quinone oxidoreductase (NQO1), antioxidant equilibrium in cells which is altered, and reactive oxygen species (ROS) [18].
Therefore, novel strategies have been explored to lower oxidative stress in Dox users and to improve treatment outcomes without compromising the anticancer potential. The use of antioxidants might to have no effect or might even modestly improve chemotherapy results [19].
Reduced Dox-induced reactive oxygen species (ROS) levels may lessen cardiotoxic side effects during TNBC treatment, also use of antioxidants during chemotherapy may benefit healthy tissues and minimize the chance of cancer recurrence. Vitamin D and its active metabolites have an antioxidant effect by activating NRF2-dependent antioxidant signalling. This may inhibit the growth of cancerous cells [20]. So, this study was performed to see whether vitamin D may counteract the cardiotoxicity caused by doxorubicin.
In our study, serum calcium was considerably higher in doxorubicin-treated group compared to other studied groups. Dysregulation of intracellular Ca2+ homeostasis is one of the prominent mechanisms behind Dox's harmful effects on mitochondria. By inhibiting SERCA2a transcription, among other mechanisms by Dox affects Ca2+ homeostasis, Ca2+ uptake into the sarcoplasmic reticulum (SR) is hampered [21]. In this concern Awad et al., [10] found that Dox can bind to and activate the ryanodine receptor (RYR2), causing the release of Ca2+ from the SR into the cytosol. In fact, after Dox intoxication, both cytosolic and mitochondrial Ca2+ markedly increased. In the past, the overabundance of Ca2+ in both the cytoplasm and mitochondria contributed to the cardiotoxicity of Dox [22].
A recent study by Lee et al. (1) reported that, low vitamin D supplementation may decrease cardiotoxic adverse effects during Dox treatment without lowering Dox efficacy. Dietary vitamin D supplementation increased plasma vitamin D levels. Mice exposed to Dox (10 mg/kg) developed cardiotoxicity after receiving two weekly injections, despite the fact that vitamin D treatment prevented cardiotoxic adverse effects in vivo as demonstrated by ECG markers such as ejection percent, stroke volume, and fractional shortening. Additionally, 4- hydroxynonenal (4-HNE) and C-Myc induced compensated cardiac hypertrophy (C-MYC) levels were decreased, also rats receiving vitamin D with Dox (10mg/kg) had much greater survival rates compared those receiving Dox (10 mg/kg) alone. [23].
The higher levels of 4-HNE, NADPH and quinone acceptor oxidoreductase (NQO) expression were consistent with elevated cardiac ROS levels induced by 10 mg/kg Dox. In contrast to rats just receiving Dox (10 mg/kg), and those received vit D had reduced levels of 4- HNE and NQO1, which may prevent 10 mg/kg Dox from producing ROS. NQO1 suppression has been shown to boost sensitivity to chemotherapeutic medicines like Dox [24]. After vitamin D administration, there was an increase in the phosphorylation of DRP1 at S637, a hallmark for mitochondrial fission inhibition. The stop of treatment with vitamin D, the Dox-induced increase in C-MYC expression in cardiac tissue, supporting earlier research that showed vitamin D can reduce C-MYC in cancer models [25]. The oxidation of polyunsaturated fatty acids by ROS to generate 4-HNE in combination with dox-induced C-MYC expression may make cardiac dysfunction worse.
In the study by Lee et al., (1), vitamin D improved cardiac function without interfering with the effect of 10 mg/kg Dox on the reduction in TNBC tumor volume. Rats that received vitamin D supplements had improved cardiac health, greater survival rates, and higher body weights than Dox-treated mice who didn’t get vit D. Rats receiving vit D supplements also saw greater declines in heart function and survival. Mice administered Dox with 6 mg/kg showed less cardiac adverse effects, but given vit D supplements, their tumors were reduced. The amount of vit D used in this study (10,000 IU/kg) is far lower than typical vit D supplement dosages; a 75 kg adult would receive 662 IU [26].
The serum cardiac troponin I concentration in the current study was significantly higher in the doxorubicin-treated group than in the studied group. In a study by Reagan et al. [27] discovered that chronic doxorubicin-induced cardiotoxicity resulted in cardiac damage at all dosages (1, 2, or 3 mg/kg/wk.). Both the incidence and the mean magnitude of cardiac troponin (cTn) signals frequently increased with increasing dose and/or longer treatment duration. The cTnT and cTnI signals correlated in the samples under investigation. Serum cTn results following a 2- or 4-week recovery period also demonstrated the continuation of cardiac injury beyond the treatment period, which consistent with the established aetiology of doxorubicin cardiomyopathy. This finding was consistent with Chaudhari et al. [28] finding GO and KEGG pathway analyses demonstrated that Dox exposure lowered the expression of genes involved in cardiac contraction and pathways related with cardiomyopathies in a preferential way. In contrast to these different gene-specific effects, exposed cardiomyocytes' cTnT and cTnI proteins underwent significant, long-lasting changes in their shape and topographical organization. The most notable ones were cytoplasmic rearrangements of cTns, where the usual bundling patterns of the cell were changed to a random accumulation that persisted throughout the entire trial. Additionally, problems with cells' contractility and beating patterns. Similar alterations in human cardiomyocytes treated with Dox have been previously reported, however without a thorough examination of the morphology of cTns. Overall, these data indicates that Dox-induced morphological and maybe functional changes in human cardiomyocytes have long-lasting effect and as a result of their persistence, lead to their delayed malfunctioning [39].
In the present study, malondialdehyde levels in cardiac tissue were considerably higher in the doxorubicin-treated group compared to other groups. While, the doxorubicin-treated group had significantly lower levels of superoxide dismutase and glutathione in comparison to other groups. Zhao et al. [30] has also shown a connection between myocardial oxidative stress and the underlying mechanisms of Dox-induced cardiotoxicity. During evolution, cells create an inherent antioxidant system to reduce ROS levels and boost cell viability. GSH, GSH-Px, and SOD are the most prominent antioxidant enzymes. The elevation of SOD, GSH, and GSH-Px levels in vivo and the downregulation of ROS levels in vitro demonstrated that Dossin protected Dox-induced oxidative damage to the myocardium [31]. In addition, Dossin significantly reduced MDA, an end-product of lipid hydroperoxide as well as one biomarker. On the same line, Alam et al., [32] found that, the reduced amount of GSH in the heart was a result of Dox treatment. Groups C and D that received thymoquinone experienced a drop in MDA level and an increase in GSH level. GSH deficiency may impede cell defence, which could result in tissue damage.
The current results demonstrate that vitamin D supplementation in the diet, whether mild or moderate, was cardioprotective and didn’t interfere with Dox ability to treat cancer in rats. It is reasonable to conduct more research to determine the ideal vitamin D dosages required to enhance heart functions without reducing Dox effectiveness.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
